Working… Menu

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03332355
Recruitment Status : Suspended (Business Reasons)
First Posted : November 6, 2017
Last Update Posted : September 22, 2020
University of Illinois at Chicago
Information provided by (Responsible Party):
Vanquish Oncology, Inc.

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : June 30, 2022